Results 241 to 250 of about 8,158 (292)

Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis. [PDF]

Alzheimers Dement
Wilson JM, Dage JL, Qian HR, Irelan CL, Crowder HS, Duffin KL, Mintun M, Brooks DA, Gerstein HC, Bethel MA.   +9 more
europepmc   +1 more source

Hypothalamic‐Pituitary‐Testicular Axis Regulation in Men With Type 2 Diabetes

Clinical Endocrinology, Volume 105, Issue 1, Page 22-23, July 2026.
Mathis Grossmann
wiley   +1 more source

Implications of GLP-1 Agonists on Office-Based Sedation and General Anesthesia for Dentistry. [PDF]

Anesth Prog
McKenzie C, DeBernardo A, Schwartz P.
europepmc   +1 more source

Differential Gastric Motility, Gut Hormone, and Appetite Changes Following A Mixed Meal in People With Obesity and Healthy Controls. [PDF]

Neurogastroenterol Motil
Javidi D, Webb DL, Diaz HO, Ud-Din M, Elias K, Sundbom M, Hellström PM.   +6 more
europepmc   +1 more source

Effect of GIP and GLP-1 infusion on bone resorption in glucose intolerant, pancreatic insufficient cystic fibrosis. [PDF]

J Clin Transl Endocrinol
Lei WS, Chen X, Zhao L, Daley T, Phillips B, Rickels MR, Kelly A, Kindler JM.   +7 more
europepmc   +1 more source

The GLP‐1 Receptor Agonist Paradox in Dermatology: Why We Cannot Afford the Knowledge Gap

International Journal of Dermatology, Volume 65, Issue 7, Page 1361-1362, July 2026.
Ramy Awadalla, Derek Davies
wiley   +1 more source

Incretins and Lipid Metabolism

Current Medicinal Chemistry, 2018
Background: Recent findings indicate that incretin hormones and incretin-based therapies may affect the metabolism of lipoproteins, although the corresponding mechanisms are not clearly defined. Objective: To summarize the available data on the mechanisms linking incretins with the characteristics of serum lipoproteins and discuss the clinical ...
Vasilis Tsimihodimos, Moses Elisaf
exaly   +4 more sources

Incretins in the Therapy of Diabetic Kidney Disease

International Journal of Molecular Sciences, 2021
Diabetic kidney disease is a microvascular complication that occurs in patients with diabetes. It is strongly associated with increased risk of kidney replacement therapy and all-cause mortality.
Agnieszka Przezak, Weronika Bielka, Andrzej Pawlik   +2 more
exaly   +2 more sources

Possible Mechanisms and Molecular Signaling of Incretins against the Development of Type 2 Diabetes Mellitus

Current Molecular Pharmacology, 2023
The increasing number of cases of diabetes mellitus (DM) and related diseases has become a global health concern. In this context, controlling blood glucose levels is critical to prevent and/or slow down the development of diabetes-related complications.
Zatollah Asemi, Alireza Mafi, Omid Vakili   +2 more
exaly   +2 more sources

The physiology and pharmacology of incretins in type 2 diabetes mellitus

Diabetes, Obesity and Metabolism, 2008
Udgivelsesdato: 2008/8Two incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide (GLP)-1, help control blood glucose levels by affecting plasma insulin levels in response to oral glucose intake - this is known as ...
Jens J Holst
exaly   +2 more sources